Therapy Areas: Infectious Diseases
Motif Bio to present new iclaprim data at ECCMID 2018
19 April 2018 -

Motif Bio (LON: MTFB) will present new clinical and pre-clinical data for its investigational drug candidate iclaprim at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018), the company disclosed on Thursday.

The global REVIVE-2 study was a Phase 3 trial evaluating iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI).

As previously reported, the study met its primary endpoint of non-inferiority when compared to the current standard of care vancomycin at the early time point, 48 to 72 hours, after the start of administration of the study drug. It was also non-inferior at the test of cure endpoint, seven to 14 days after study drug discontinuation.

At the conference, the company will present more detailed safety results. Iclaprim was found to be well tolerated in the trial, with 75% of adverse events in the study categorised as mild.

There were no reports of study-drug related treatment emergent adverse events related to nephrotoxicity (kidney toxicity) for patients receiving treatment with iclaprim, compared to two (0.7%) for vancomycin. There were no deaths in the iclaprim arm but one in the vancomycin group.

Login
Username:

Password: